Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cedars-Sinai Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011921
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pain, hirschsprung’s disease, nasal polyps, abnormal bleeding, head and neck pain, nosebleeds, pancreatic cancer, and varicocele. Its various programs and services include blood donor services, blood and marrow transplant program, epilepsy program, carcinoid and neuroendocrine tumor program, and nutrition counseling services, among others. Cedars-Sinai also offers continuing education for medical professionals, resources for physicians, and nursing programs. The center offers research in the areas of diabetes and obesity, cancer, digestive diseases, endocrinology, genetics and genomics. Cedars-Sinai is headquartered in Los Angeles, California, the US.

Cedars-Sinai Medical Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cedars-Sinai Medical Center, Medical Devices Deals, 2011 to YTD 2017 10
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Naia Rare Diseases to Raise Funds through Series B Financing 13
Emulate Raises USD12 Million in Series A Financing 14
Partnerships 15
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 15
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 16
Treeway Enters into Agreement with Cedars-Sinai Medical Center 17
Cedars-Sinai To Form Joint Venture With UCLA Health System And Select Medical 18
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 19
Licensing Agreements 20
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 20
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 22
EOS Biosciences Enters into Licensing Agreement with Cedars-Sinai Medical Center 23
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 24
BioSante Pharma Amends Licensing Agreement with Wake Forest University and Cedars-Sinai 26
Equity Offering 27
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 27
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 28
Cedars-Sinai Medical Center – Key Competitors 30
Cedars-Sinai Medical Center – Key Employees 31
Cedars-Sinai Medical Center – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Government and Public Interest 34
Feb 01, 2017: New treatment regimen extends life for some men with recurrent prostate cancer, study finds 34
Dec 05, 2016: Cedars-Sinai Receives $10 Million for Pioneering Research on Debilitating Digestive Tract Disease 35
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 36
Sep 12, 2016: Semma Therapeutics Announces $5 Million Grant from California Institute of Regenerative Medicine to Develop Novel Stem-Cell Derived Treatment for Diabetes 38
Jul 19, 2016: ALS research suggests stem cells be ‘aged’ to speed progress toward finding treatments 39
Jun 28, 2016: UCLA Clinical and Translational Science Institute receives $69.6 million grant from NIH 40
Product Approvals 42
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Key Facts 2
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cedars-Sinai Medical Center, Deals By Therapy Area, 2011 to YTD 2017 9
Cedars-Sinai Medical Center, Medical Devices Deals, 2011 to YTD 2017 10
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Naia Rare Diseases to Raise Funds through Series B Financing 13
Emulate Raises USD12 Million in Series A Financing 14
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 15
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 16
Treeway Enters into Agreement with Cedars-Sinai Medical Center 17
Cedars-Sinai To Form Joint Venture With UCLA Health System And Select Medical 18
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 19
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 20
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 22
EOS Biosciences Enters into Licensing Agreement with Cedars-Sinai Medical Center 23
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 24
BioSante Pharma Amends Licensing Agreement with Wake Forest University and Cedars-Sinai 26
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 27
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 28
Cedars-Sinai Medical Center, Key Competitors 30
Cedars-Sinai Medical Center, Key Employees 31
Cedars-Sinai Medical Center, Other Locations 32
Cedars-Sinai Medical Center, Subsidiaries 33

★海外企業調査レポート[Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CIMB Private Banking:企業の戦略・SWOT・財務情報
    CIMB Private Banking - Strategy, SWOT and Corporate Finance Report Summary CIMB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Illumina, Inc.:企業のM&A・事業提携・投資動向
    Illumina, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Illumina, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Guardant Health Inc (GH):企業の製品パイプライン分析2018
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • Correvio Pharma Corp (COM):製薬・医療:M&Aディール及び事業提携情報
    Summary Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, fo …
  • Nielsen Holdings PLC:企業のM&A・事業提携・投資動向
    Nielsen Holdings PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nielsen Holdings PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • HORNBACH-Baumarkt-AG (HBM):企業の財務・戦略的SWOT分析
    HORNBACH-Baumarkt-AG (HBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • University of Toronto-製薬・医療分野:企業M&A・提携分析
    Summary University of Toronto (UT) is an educational and research service provider that offers undergraduate and postgraduate courses in various fields. The university offers courses in various fields such as applied science and engineering, architecture, landscape, design, arts and science, continu …
  • Jack Henry & Associates, Inc.:企業の戦略・SWOT・財務情報
    Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • National Bank Of Kuwait Sak:企業の戦略・SWOT・財務分析
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Procurri Corporation Limited (BVQ):企業の財務・戦略的SWOT分析
    Procurri Corporation Limited (BVQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • The Tokyo Star Bank Ltd:企業の戦略・SWOT・財務情報
    The Tokyo Star Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Star Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Israel Aerospace Industries Ltd:戦略・SWOT・企業財務分析
    Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Hester Biosciences Ltd (HESTERBIO):企業の財務・戦略的SWOT分析
    Hester Biosciences Ltd (HESTERBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Delticom AG:企業の戦略・SWOT・財務情報
    Delticom AG - Strategy, SWOT and Corporate Finance Report Summary Delticom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • MEI Pharma Inc (MEIP):企業の財務・戦略的SWOT分析
    MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Centrose LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Centrose LLC (Centrose) is a precision drug company that develops medicines to target diseased tissues. The company's product pipeline includes EDC1 (Dysadherin), EDC2 (CD147), EDC3 (CD98), EDC5 (CD44), and EDC8 (CD38). Its product EDC1 combines two proteins found in close proximity to treat …
  • Coutts & Co.:企業の戦略・SWOT・財務情報
    Coutts & Co. - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Crossject SA (ALCJ)-医療機器分野:企業M&A・提携分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company offers products which include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a pipeline of supergenerics by …
  • MSC Industrial Direct Co Inc (MSM):企業の財務・戦略的SWOT分析
    MSC Industrial Direct Co Inc (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Harbor MedTech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Harbor MedTech Inc (Harbor MedTech) is a commercial-stage regenerative medicine company that offers tissue regeneration solutions. The company offers Architect, an extracellular collagen matrix used in managing partial and full thickness wounds. Its collagen wound matrix systems are used in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆